Qingdao Respiratory Industry Conference and the 23rd Respiratory Week Opens Registration: Three Key Highlights to Anticipate
In 2024, the field of respiratory medicine witnessed several historic milestones. On the policy front, chronic obstructive pulmonary disease (COPD) was finally included in China’s National Basic Public Health Services Program, marking a breakthrough advancement in the country’s prevention and control efforts for COPD.1; On the clinical front, the widespread promotion of the novel concept of “concurrent management of lung cancer and COPD” has brought new perspectives to the standardization of diagnosis and treatment for patients with these comorbidities; on the market front, AstraZeneca’s innovative monoclonal antibody therapy has received approval from the National Medical Products Administration (NMPA), marking the entry of severe asthma into an era of biologic targeted precision therapy and offering patients new hope and options.2。
Amid numerous achievements, China’s respiratory medicine discipline is steadily advancing toward high-quality development. To further promote comprehensive lung health care and the growth of the lung health industry, create a platform for collaboration among academia, research, and industry, attract innovative industrial resources, and build an ecosystem for the respiratory health industry, the “2024 Qingdao Respiratory Industry Conference and the 23rd Respiratory Week” will be held in Qingdao, Shandong Province, on October 26.
The conference brought together guests from six key sectors: government, industry, academia, research, healthcare, and investment. It attracted nearly 1,000 participants, including top national experts in respiratory medicine, leaders of pharmaceutical companies, and prominent figures from the investment community. Discussions covered a wide range of topics, including biologics, chronic obstructive pulmonary disease (COPD), bronchial asthma, lung cancer, pediatric respiratory care, pulmonary infections, and innovative industrial ecosystems. The event aimed to promote the development of an industrial cluster in Qingdao and contribute to achieving the grand goals of “Healthy China 2030.”
The conference features one main forum and seven sub-forums. The main forum will host forward-looking and authoritative dialogues on macro-level topics, including breakthroughs in technical therapies for respiratory diseases, refinement of prevention and treatment protocols, and the interpretation and implementation of policies. The seven sub-forums will focus more narrowly, offering in-depth explorations of “respiratory” topics from various perspectives.
Among them,Industry Innovation ForumSettingsTwo Major Sections：On one hand, it interprets innovative diagnosis and treatment models, implements the integration of medical care and prevention, and reshapes a new ecosystem for hierarchical and collaborative respiratory diagnosis and treatment; on the other hand, it invites high-quality enterprises to conduct roadshows, showcasing cutting-edge technological solutions in the fields of chronic respiratory diseases and respiratory interventions.。
In addition to the forum content, the conference has specially set up an industry marketplace area to showcase outstanding innovation cases from companies in the industry.
This forum serves not only as a platform for stakeholders across the respiratory industry ecosystem to exchange ideas, collaborate, and voice their perspectives, but also as a special invitation to attract more participants into the new respiratory industry ecosystem. The conference features three major highlights:
Frontier Academic Feast:Industry Forward-Looking Insights, Hot Trends in Respiratory Technology, and First-Line Clinical Experience—All in One Place
In-Depth Exchange with Industry Leaders:Direct offline engagement with CDC policy experts, academicians-level academic experts, leaders of innovative enterprises in the field of respiratory health, and heads of leading investment institutions
Precision Resource Targeting:AstraZeneca’s Respiratory Ecosystem: Comprehensive Access to Clinical, Government Investment Promotion, and Upstream/Downstream Enterprise Resources
AstraZeneca sincerely invites you to scan the QR code below to participate as a guest in “Industry Innovation Forum”, gain access to the most cutting-edge innovative information in the field of respiratory medicine, and obtain opportunities to communicate with investors and industry experts.Registration Deadline: October 20。
Welcome to scan the QR code and fill in your information to register for the conference.
As a multinational pharmaceutical company with over 30 years of deep commitment to China, AstraZeneca has been enhancing the standards of respiratory diagnosis and treatment in China through multiple dimensions, including introducing innovative medicines, exploring novel diagnostic and therapeutic approaches, promoting the translation of medical research into clinical practice, pioneering innovative models, and strengthening respiratory-related disciplines. In Shandong Province alone, AstraZeneca has implemented numerous innovative projects within the respiratory industry.
On one hand, AstraZeneca is accelerating the introduction of innovative drugs and promoting “Made in China, locally produced.”To accelerate patient access to innovative medicines, AstraZeneca has signed a strategic cooperation memorandum with the Shandong Medical Products Administration. The two parties will explore deeper collaboration in areas such as drug review and approval, product registration and market launch, and drug testing for rare diseases, respiratory conditions, and other therapeutic areas. In 2024, AstraZeneca further increased its investment in its Qingdao aerosol production and supply base, bringing the total investment to USD 750 million, which fully demonstrates its confidence and commitment to deepening its development in China.
On the other hand, AstraZeneca has strengthened innovation collaborations by integrating resources from government, industry, academia, research institutions, healthcare providers, and investors to create an integrated solution for innovative diagnosis and treatment of respiratory diseases.At the 2023 Qingdao Respiratory Industry Conference, AstraZeneca unveiled the Qingdao Medical Research Achievement Transformation Base, further supporting Qingdao’s efforts to build a world-class biomedical industry chain. Leveraging its Qingdao Regional Headquarters, AstraZeneca has successively established the Qingdao International Life Science Innovation Park and the Qingdao Smart Healthcare Innovation Center, providing multi-dimensional empowerment to the development of industrial and regional innovation ecosystems.
Furthermore, AstraZeneca is fully supporting Qingdao in establishing a comprehensive prevention and control system and management model for chronic respiratory diseases, enhancing the capacity of primary healthcare institutions in screening, diagnosis rates, and standardized treatment for these conditions. The company is also facilitating the development of cough and asthma management centers to promote standardized diagnosis and treatment in the field of chronic diseases.
AstraZeneca has always upheld its original aspiration of being “patient-centric,” continuously addressing the unmet needs of patients with respiratory diseases in China. It aims to collaborate with a broader ecosystem of partners from government, industry, academia, research institutions, healthcare providers, and investment sectors to co-create and build a robust respiratory industry ecosystem in China.
Meeting Time:October 26, 2024
Main Venue: 8:20 AM–12:40 PM
Industry Innovation Forum: 13:30–17:45
Venue:Shangri-La Hotel, Qingdao (No. 9 Hong Kong Middle Road, Shinan District, Qingdao City)
Main Venue: Shengshi Hall
Industry Innovation Forum: Multifunctional Hall 22
Target Audience Statement:
This material is provided by AstraZeneca for reference only by healthcare professionals and individuals working in the healthcare industry, and is not intended for promotional purposes.
Approval Number: CN-144936, Valid until November 9, 2024
1. National Health Commission Primary Healthcare Department Document [2024] No. 31
2. Jian Shi Ju [Internet] Targeting Severe Asthma! AstraZeneca’s Innovative Monoclonal Antibody Therapy Approved for Market Launch[Source: August 21, 2024]